Maria Z & Ricky S make this job unbearable. Many of my physicians have told me not to bring either of them
around. The company has a terrible culture. When I came onboard I worked with Andrew, the recruiter. He is like a cringe game show host with no talent or professionalism. This was the worst career decision I’ve made.
The company could not have reached its full potential for decades. This is an organizational problem and cannot be overcome under current management structure. Let them drift and watch.
Just an equipment maker. Do not expect any expertise. Worse, their new masters NN do not understand these processes neither. Management not having a clue pushes employees to produce AI generated generic reviews that they do not understand and cannot explain. Then pushes them out. Even Singh Singh cannot help them. Circus from a little town.
Drug price corrections would result in payroll reduction and this is a chance to remove workers from two large countries who steal technology and jobs from americans
Bioparin deal with Inozyme for 270M is dwarfed by posts on Novo Nordisk and Lilly deals that go into billions. This is the appearance by the CEO and Business Development pretending to be active. Inozyme is a weak company and enzyme drugs prospects are stagnant. Lack of vision and mismanagement.
We at Lilly may question the decision of spending $1.3B on Rznomics and the RNA technology of hearing restoration since nothing could come out of it, but that decision was not as bad as series of Novo Nordisk decisions. Back to the old dumb and dumber race. Novo Nordisk used to look down on us, but they ended dumber after all. Let's enjoy at last.
Adding to the Novo Nordisk post. SUS has been founded in 2017. Their expertise was nil. The company used the Me Too business model, building hardware employing principles introduced by others decades ago. Their entry into US was a disaster. To attract Novo Nordisk they temporarily invited Mr Singh to provide a front. Novo took the bait, since they had no expertise in the field at all.
Novo Nordisk has mastered technologies that are mature or obsolete now and lacks in-house expertise not only to conduct research and development, but even be able to evaluate technologies that can benefit the company. The 2024 examples can be putting 1.46B USD into Neomorph to develop molecular glues technology. This was not well researched decision. The company had excess of cash and underestimated competition in the GLP1 markets as lasting cash source. Selection of Neomorph was flawed. Different field at smaller scale was acquiring 60% of Single Use Systems. They did not fit into Novo Nordisk business model, did not have original technologies, but NN lacked expertise in single use systems and could not properly do the due diligence. It was blindly wanting to replace many obsolete small scale stainless steel systems with disposables.
It is not appropriate to discuss who was responsible for these decisions, but there were more similar blunders. The profile of workforce and hiring practices could be the factors.
These days of drug price cutting will see layoffs across the whole pharma spectrum. Large companies are notoriously wasteful in many respects including artificially inflated workforce. Small companies operate more efficiently. They will all suffer, the large companies through layoffs and small companies by layoffs and going under. Foreign companies would adjust too due to decrease in the US revenues.
Result will be more balanced international landscape with American patients being more fairly treated. Finally! Even if it means fewer opportunities for international leaches.
